DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML
Product details
Registration number: SIN15111P
Classification: Prescription Only
Active ingredients: daratumumab
Strength: 400mg/20mL
Dosage form: INFUSION, SOLUTION CONCENTRATE
Route: INTRAVENOUS
Registrant: JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD
ATC code: L01XC24
HSA approval date: 26 October 2016
Manufacturer(s): Cilag A.G.
Manufacturing country/countries: SWITZERLAND
What are the HSA registration number and classification for DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML?
According to the HSA dataset updated 7 August 2026:
Registration number: SIN15111P
Classification: Prescription Only
What active ingredients and strength are recorded for DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML?
According to the HSA dataset updated 7 August 2026:
Active ingredients: daratumumab
Strength: 400mg/20mL
Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.
What dosage form and route are recorded for DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML?
According to the HSA dataset updated 7 August 2026:
Dosage form: INFUSION, SOLUTION CONCENTRATE
Route: INTRAVENOUS
Who is the recorded registrant for DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML?
According to the HSA dataset updated 7 August 2026:
Registrant: JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD
Which manufacturers and countries are listed for DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML?
According to the HSA dataset updated 7 August 2026:
Manufacturer(s): Cilag A.G.
Manufacturing country/countries: SWITZERLAND
Where can I look up DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML in the HSA register?
Open HSA’s therapeutic product register and search for registration number SIN15111P or the exact product name DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML. The general register link does not preselect this product.
What are the source dates for this DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML record?
This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.
The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.
Has this DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML record had a separate HSA register check?
No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.
Search the HSA register using SIN15111P for the latest record.
Sources and dates
HSA dataset: 2026. Updated: 13 November 2026.
Factual product information only; no dosing, treatment or suitability advice.
Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.
.png)